NR4A1 and non-small cell lung carcinoma: For instance, hormone receptor-positive (HR-positive) breast cancer and non-small cell lung cancer (NSCLC) are two prime examples where systematic molecular profiling has fundamentally altered therapeutic strategies [20,21].